We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Study of Plasma Bicalutamide Concentrations in Hemodialysis Patients.
- Authors
Ito, Fumio; Goya, Nobuyuki; Nakazawa, Hayakazu; Suzuki, Toshiaki; Suzuki, Keiko; Kubo, Kazuo; Kihara, Takeshi
- Abstract
Bicalutamide is an anti-androgen that is used worldwide to treat prostate cancer (CaP). However, there are no data on blood bicalutamide concentrations in hemodialysis (HD) pa-tients with CaP. Therefore, we investigated the plasma levels of bicalutamide during the peridialysis period in this popula-tion. The study group included 5 HD patients with CaP who had been treated with bicalutamide (80 mg/day) for at least 3 months. Blood samples were taken during and between HD sessions and the plasma concentrations of the active R enan-tiomer (R-bicalutamide) were assessed using an HPLC assay. The plasma R-bicalutamide levels on the non-dialysis day were measured In 2 patients (patients 1 and 2) immediately before dosing and 8 and 24 h after dosing. These levels were 18,730,19,090 and 19,420 ng/ml (patient 1), and 4,522,4,581, and 5,296 ng/ml (patient 2), respectively. The mean plasma levels of R-bicalutamide in all 5 subjects just before HD, and 2 and 4 h after the start of HD were 8,726, 9,354 and 10,068 ng/ml, respectively. These results show that bicalutamide does not accumulate and is not diluted in the blood circula-tion of HD patients when given at the normal dosage used in the general population.
- Subjects
HEMODIALYSIS patients; ANTIANDROGENS; BLOOD plasma; PROSTATE cancer treatment; PHARMACOKINETICS; HIGH performance liquid chromatography
- Publication
Urologia Internationalis, 2012, Vol 89, Issue 2, p162
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000339919